Celldex Therapeutics (CLDX)
(Delayed Data from NSDQ)
$22.19 USD
+0.21 (0.96%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $22.21 +0.02 (0.09%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, Celldex Therapeutics, Inc. has a market cap of $1.46B, which represents its share price of $21.98 multiplied by its outstanding shares number of 66.38M. As a small-cap company, CLDX's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
CLDX 22.19 +0.21(0.96%)
Will CLDX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CLDX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CLDX
scPharmaceuticals (SCPH) Soars 8.8%: Is Further Upside Left in the Stock?
Xenon Pharmaceuticals (XENE) Up 8.7% Since Last Earnings Report: Can It Continue?
CLDX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Celldex Therapeutics (CLDX) Reports Q1 Loss, Lags Revenue Estimates
Cytokinetics (CYTK) Moves 5.4% Higher: Will This Strength Last?
Celldex Therapeutics (CLDX) Reports Q4 Loss, Lags Revenue Estimates
Other News for CLDX
Interesting CLDX Put And Call Options For September 19th
RBC downgrades Jasper Therapeutics on questions about briquilimab
Celldex Therapeutics’ Promising Phase 2 Study on Eosinophilic Esophagitis
Celldex’s Phase 3 Study on Barzolvolimab: A Potential Game-Changer for Chronic Urticaria
Celldex Therapeutics Advances Phase 2 Study on Barzolvolimab for Prurigo Nodularis